Role of PARP inhibitors in cancer biology and therapy.
Curr Med Chem
; 19(23): 3907-21, 2012.
Article
en En
| MEDLINE
| ID: mdl-22788767
ABSTRACT
Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology heralded the clinical development of poly(ADP-ribose) polymerase (PARP) inhibitors. Although initially developed to exploit synthetic lethality in models of cancer associated with defective DNA repair, our burgeoning knowledge of PARP biology has resulted in these agents being exploited both in cancer with select chemotherapeutic agents and in non-malignant diseases. In this review article, we briefly review the mechanisms of DNA repair and pre-clinical development of PARP inhibitors before discussing the clinical development of the various PARP inhibitors in depth.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inhibidores Enzimáticos
/
Inhibidores de Poli(ADP-Ribosa) Polimerasas
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Curr Med Chem
Asunto de la revista:
QUIMICA
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos